All
Self-regulation key in addressing industry conflicts of interest
July 1st 2006National report - Although the pharmaceutical industry and medical professional organizations have guidelines regarding physician relationships with industry, it is incumbent on individual professionals to apply those guidelines in such a way that they will maintain public trust and continue to serve their patients' best interests, says Stephen B. Webster, M.D., department of dermatology, Gundersen Lutheran Medical Center, La Crosse, Wis.
Langerhans cells dampen contact hypersensitivity
July 1st 2006New Haven, Conn. - Epidermal Langerhans cells (LCs), long thought to play a role in the initiation of contact hypersensitivity (CHS), appear to actually have quite the opposite function in the development of CHS responses, according to a report recently published in Immunity.
Safety standards evolving for nonhospital laser use
July 1st 2006Boston - Among the most important developments in safety standards that impact dermatology practices are changes involving laser use in non-hospital settings and development of international standards for intense pulsed light (IPL) devices, according to Penny J. Smalley, R.N., a Chicago-based safety consultant.
Studies demonstrate safety, efficacy of CaHA for facial lipoatrophy
July 1st 2006National report - Results of two parallel, prospective, open-label, North American studies demonstrate that treatment with the injectable filler consisting of microspheres of calcium hydroxylapatite (CaHA) in a carboxymethylcellulose gel carrier (Radiesse, BioForm Medical) provides safe, immediate and relatively durable restoration of facial volume in patients with HIV-associated lipoatrophy.
Use of aspirin/warfarin seems safe for derm surgery patients
July 1st 2006National report - When it comes to the issue of perioperative management of existing anticoagulant and antiplatelet therapy in patients undergoing cutaneous procedures, results of a mail survey indicate most British dermatologists are continuing those medications and without untoward consequences, reports Claudia V. DeGiovanni, M.D.
Monkeypox outbreak lessons: More awareness, funding needed
July 1st 2006National report - Present concerns about the spread of avian flu are a reminder that two years ago in the Midwest, another animal-carried virus - monkeypox - at least momentarily threatened to spread to more areas and infect more victims.
Topical urea in EFA-base vehicle most effective barrier
July 1st 2006National report - A novel product formulating 40 percent urea in an essential fatty acid (EFA) vehicle (Umecta, JSJ Pharmaceuticals) appears to be a good choice for treating skin conditions associated with hyperkeratosis, scaling and compromised barrier function, according to Peter M. Elias, M.D., professor of dermatology, University of California, San Francisco, and a staff physician at the Veterans Administration Medical Center, San Francisco.
Acne trial suggests strategies for enhancing outcomes with blue light
July 1st 2006National report - Results of a multicenter, phase 2 randomized clinical trial are providing new perspectives on use of blue light therapy (BLU-U, DUSA Pharmaceuticals) for the treatment of moderate and severe acne vulgaris.
Dermatologists should be on the lookout for OCD 'red flags'
June 1st 2006National report - The prevalence of obsessive-compulsivedisorder (OCD) in certain dermatologic settings outside of skincancer - such as itchy dermatosis - can be as high as14 percent to 20 percent, compared to a prevalence of 2 percent to3 percent in the general population.